Catalyst Biosciences (NASDAQ:CBIO) Share Price Crosses Above Two Hundred Day Moving Average of $0.29

Catalyst Biosciences, Inc. (NASDAQ:CBIO) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.29 and traded as high as $0.55. Catalyst Biosciences shares last traded at $0.45, with a volume of 1,163,000 shares changing hands.

Catalyst Biosciences Stock Performance

The business’s fifty day moving average is $0.41 and its 200-day moving average is $0.29. The firm has a market cap of $17.26 million, a P/E ratio of -0.30 and a beta of 1.02.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings results on Thursday, August 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). Analysts predict that Catalyst Biosciences, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Trading of Catalyst Biosciences

Several hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Catalyst Biosciences by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,186,986 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 85,716 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Catalyst Biosciences in the 1st quarter worth about $52,000. Bank of New York Mellon Corp grew its position in Catalyst Biosciences by 187.9% in the 1st quarter. Bank of New York Mellon Corp now owns 216,807 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 141,498 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in Catalyst Biosciences in the 2nd quarter worth about $36,000. Institutional investors and hedge funds own 5.98% of the company’s stock.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.